about
Mechanism of Platinum Derivatives Induced Kidney InjuryThe role of drug transporters in the kidney: lessons from tenofovirGastrointestinal injury associated with NSAID use: a case study and review of risk factors and preventative strategiesHigh-throughput imaging-based nephrotoxicity prediction for xenobiotics with diverse chemical structuresEfficacy and safety of amphotericin B lipid-based formulations-A systematic review and meta-analysis.Glomerular capillary hemorrhage induced in rats by diagnostic ultrasound with gas-body contrast agent produces intratubular obstruction.Bioprinting of 3D Convoluted Renal Proximal Tubules on Perfusable ChipsAcute kidney injury in solid organ transplant recipients.Kidney injury molecule-1 outperforms traditional biomarkers of kidney injury in preclinical biomarker qualification studies.Hypertensive disorders of pregnancy and the recent increase in obstetric acute renal failure in Canada: population based retrospective cohort study.Supervised prediction of drug-induced nephrotoxicity based on interleukin-6 and -8 expression levels.Targeted therapy of colorectal neoplasia with rapamycin in peptide-labeled pegylated octadecyl lithocholate micelles.Drug-Induced Nephrotoxicity and Dose Adjustment Recommendations: Agreement Among Four Drug Information SourcesA novel TXNIP-based mechanism for Cx43-mediated regulation of oxidative drug injuryIntegrated transcriptomic and proteomic analyses uncover regulatory roles of Nrf2 in the kidney.Mechanistic biomarkers for cytotoxic acute kidney injury.Satkara (Citrus macroptera) Fruit Protects against Acetaminophen-Induced Hepatorenal Toxicity in Rats.Novel assays for detection of urinary KIM-1 in mouse models of kidney injuryCytoplasmic initiation of cisplatin cytotoxicity.Association Between the Use of Proton Pump Inhibitors and the Risk of ESRD in Renal Diseases: A Population-Based, Case-Control Study.Analysis of renal function during telaprevir-based triple therapy for chronic hepatitis CBeneficial effects of fermented black ginseng and its ginsenoside 20(S)-Rg3 against cisplatin-induced nephrotoxicity in LLC-PK1 cells.Biochemical mechanisms of nephrotoxicity: application for metabolomics.The kidney in the critically ill.Chronic Kidney Disease, Fluid Overload and Diuretics: A Complicated Triangle.A look at risk factors of proteinuria in subjects without impaired renal filtration function in a general population in Owerri, NigeriaAcute Kidney Injury: Definition, Pathophysiology and Clinical PhenotypesPathophysiology of acute kidney injury3D Proximal Tubule Tissues Recapitulate Key Aspects of Renal Physiology to Enable Nephrotoxicity Testing.Acute and chronic acetaminophen use and renal disease: a case-control study using pharmacy and medical claims.Metabolomics for early detection of drug-induced kidney injury: review of the current status.Promise of new translational safety biomarkers in drug development and challenges to regulatory qualification.Role of transporters in drug interactions.Detection and management of nephrotoxicity during drug development.Renal safety in patients treated with bisphosphonates for osteoporosis: a review.Tissue-engineered kidney disease models.Cell- and biomarker-based assays for predicting nephrotoxicity.Emerging areas of research in the assessment of pharmacokinetics in patients with chronic kidney disease.Implementation of CE-MS-identified proteome-based biomarker panels in drug development and patient management.Topographically-patterned porous membranes in a microfluidic device as an in vitro model of renal reabsorptive barriers
P2860
Q26783436-CFD38430-1AAD-44CC-B5D3-A8EAC0B4E122Q26866489-33DA79CD-7408-4C84-9E22-6FD43DB00BDCQ27026351-1D06A77C-40EB-45ED-B54F-AA3B75817654Q28821950-D069D7BE-2AC1-47BD-9514-25A9259F346EQ30240770-9073E309-2D7F-4274-BBEF-6025FA84EBC9Q30481781-4333A053-CD2C-4824-873D-0FD1F325B6F2Q30820165-D5CFA587-DF29-4A3E-97F6-6026E6D2EF12Q33378684-EA82E649-3ABF-402D-B836-78970491F23FQ33913977-7A92C25E-A75E-4E46-9D91-AE17A0AE9143Q33972739-84F37888-405F-4252-B20A-1FA9E5F6F18AQ34913513-1D0CB359-4CB1-4A91-9428-E8231C1D4439Q35019696-A95843DD-3A1E-4594-A535-BD5F9713D3CBQ36102491-3AC3B80F-BF3E-40D7-B11D-C6BFD752A4BEQ36125404-26FE3AE5-D372-4AEE-BDCB-554253794D2CQ36364169-0905324A-AC38-4E8F-826D-0CB09D2CA493Q36609753-49531BFA-B352-4606-A3E0-5C016638BECBQ36680990-B4EBB0A2-B82D-4B5A-8637-1E531728EB89Q36752670-89617F55-DDDD-4ED6-AA69-567400351796Q36807108-0DBF66B7-6CE8-49C3-8D23-3E353BB17BE2Q36822474-21BC38FE-B55A-486A-9761-E61016A9A358Q36824924-E36DC57A-6E96-43B0-8E12-5D5826BA6216Q36835755-5105ADBF-3315-4423-9FC6-5A494005EE2AQ36909319-272F89E2-FDB5-4409-AA6C-66CD85C87C7EQ36938144-31C26C6A-5CA2-4BC4-9B1C-115721D68A5BQ37115621-9C780712-2230-4CDD-9903-8D44F3B35409Q37131280-1F9C3058-9DF8-481F-ADD2-C7F56F1D0573Q37543501-17E1FC8E-EF85-4793-886C-2B0DB682F010Q37574787-ED5AC7B5-05D3-4E88-A074-984D2BEAC52FQ37685354-123E2EF7-320B-420E-9A91-6A4AFE0C276EQ37724114-2375E44A-F9D8-43C8-9806-A4D020F4D4B8Q37810166-01D52535-75CA-40F4-82CB-7CB14CD94D9FQ37921314-F580728E-3625-459B-9CA4-9CE7EA7F6C15Q37964577-A6A5D360-5CC5-4DC5-AE70-DFB2E3A5CC4FQ38012203-C20ED2BB-305D-457B-B562-118DFBC96D33Q38125952-AE3E5914-21CA-4307-8159-62E9D121E23DQ38173179-76465290-B0F4-4220-8478-88EF1821DB72Q38266417-57C5C7C0-88D8-49A7-BDB6-990110C22A13Q38287050-7D6A9784-B9DD-4A98-9DDC-DDDA9ED3C67AQ38906256-47941935-9151-4E9B-9D82-CCDE9C3FEBF5Q39157681-07E25F55-CB5A-4045-828E-1026A5A2D14C
P2860
description
2006 nî lūn-bûn
@nan
2006 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
Drug-associated renal dysfunction and injury.
@ast
Drug-associated renal dysfunction and injury.
@en
Drug-associated renal dysfunction and injury.
@nl
type
label
Drug-associated renal dysfunction and injury.
@ast
Drug-associated renal dysfunction and injury.
@en
Drug-associated renal dysfunction and injury.
@nl
prefLabel
Drug-associated renal dysfunction and injury.
@ast
Drug-associated renal dysfunction and injury.
@en
Drug-associated renal dysfunction and injury.
@nl
P2860
P356
P1476
Drug-associated renal dysfunction and injury.
@en
P2093
Devasmita Choudhury
Ziauddin Ahmed
P2860
P356
10.1038/NCPNEPH0076
P577
2006-02-01T00:00:00Z